Management of Asymptomatic Bacteriuria in Pregnancy
All pregnant women should be screened for asymptomatic bacteriuria with urine culture at least once in early pregnancy (12-16 weeks), and if positive, treated with antibiotics for 3-7 days to prevent pyelonephritis, preterm birth, and low birthweight infants. 1
Why Treatment is Essential in Pregnancy
Pregnant women with asymptomatic bacteriuria face a 20-30 fold increased risk of developing pyelonephritis compared to those without bacteriuria 1. Without treatment, 20-35% of bacteriuric pregnant women will develop pyelonephritis, but with antibiotic therapy this drops dramatically to 1-4% 1. This represents one of the few clinical scenarios where treating asymptomatic bacteriuria demonstrably improves morbidity outcomes.
The evidence is robust despite being older: multiple randomized controlled trials consistently show that antibiotic treatment reduces:
- Pyelonephritis (RR 0.23,95% CI 0.13-0.41) 2
- Low birthweight infants (RR 0.64,95% CI 0.45-0.93) 2
- Preterm delivery (RR 0.27,95% CI 0.11-0.62) 2
Implementation programs in Spain and Turkey demonstrated reductions in pyelonephritis rates from 1.8-2.1% down to 0.5-0.6% with screening and treatment protocols 1.
Screening Protocol
Use urine culture as the screening test - not urinalysis or dipstick 1. Pyuria has only ~50% sensitivity for identifying bacteriuria in pregnant women and is not an indication for treatment by itself 1.
Timing: Screen at least once in early pregnancy, ideally at 12-16 weeks gestation 1. A Swedish study concluded that a single urine culture at week 16 was optimal 1.
Diagnostic criteria: Two consecutive voided urine specimens showing ≥10⁵ CFU/mL of the same bacterial strain 1.
Treatment Approach
Duration: Treat for 3-7 days 1. While the optimal duration remains somewhat uncertain, evidence suggests:
- Single-dose therapy is less effective than 4-7 day courses 3
- A 7-day course of nitrofurantoin was more effective than single-dose in preventing low birthweight (RR 1.65,95% CI 1.06-2.57) 3
- Continuous therapy to term versus 14 days followed by surveillance showed similar outcomes 1
Antibiotic selection: Nitrofurantoin and sulfonamides were the most commonly used agents in the landmark trials 1. The 2024 EAU guidelines suggest standard short-course treatment or single-dose fosfomycin trometamol as options 4, though fosfomycin data for pregnancy outcomes remain limited 3.
Post-treatment surveillance: Perform periodic screening for recurrent bacteriuria after completing therapy 1. Women with initially negative cultures still have a 1-2% risk of developing pyelonephritis later in pregnancy 1.
Critical Distinction: Pregnancy is Different
This is the only population where screening and treating asymptomatic bacteriuria is strongly recommended. The same guidelines explicitly recommend against screening or treating ASB in:
Emerging Perspective: Risk-Stratified Approach
A 2025 position paper proposes selective screening only for pregnant women with additional risk factors (previous UTI, diabetes, urinary tract abnormalities, immunosuppression, or history of preterm birth) rather than universal screening 5. However, this contradicts established IDSA guidelines and should not be implemented without further validation, as the universal screen-and-treat approach has decades of supporting evidence and is the current standard of care.
Common Pitfalls to Avoid
- Don't treat pyuria alone - it's not an indication for antibiotics without positive culture 1
- Don't use urinalysis for screening - only urine culture is adequate 1
- Don't skip post-treatment surveillance - recurrence is common and requires monitoring 1
- Don't extrapolate to non-pregnant populations - treatment benefits are unique to pregnancy 1, 3